112 - A Whole New World? Respiratory Syncytial Virus in the Vaccine and Monoclonal Antibody Era

Friday, October 18, 2024

10:30 AM – 11:45 AM US PT

Location: Ballroom (West Hall B)

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Lisa Jackson, MD, MPH (she/her/hers)

Senior Investigator
Kaiser Permanente Washington Health Research Institute
Seattle, WA, United States
C. Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics, Infectious Diseases
Baylor College of Medicine
Houston, TX, United States

Faculty(s)

Helen Chu, MD, MPH

Professor
Medicine
University of Washington
Seattle, WA, United States
Fiona Havers, MD MHS (she/her/hers)

Medical officer
Centers for Disease Control and Prevention
Atlanta, GA, United States
Amadea Britton, MD, SM

Medical Officer, Co-Lead ACIP Adult RSV Work Group
NCIRD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s):

Lisa Jackson, MD, MPH: No financial relationships to disclose

C. Mary Healy, MD, FIDSA: Dexcom Inc: Stocks/Bonds (Public Company); Hillevax, Inc: Member of Advisory board; Intuitive Surgical Inc: Stocks/Bonds (Public Company); Quidel Corporation: Stocks/Bonds (Public Company); Vapotherm: Stocks/Bonds (Public Company)

Helen Y. Chu, MD, MPH: Abbvie: Advisor/Consultant; Merck: Advisor/Consultant; Vir: Advisor/Consultant

Fiona Havers, MD MHS: No financial relationships to disclose

Amadea Britton, MD, SM: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify the impact of maternal rsv vaccination and use of monoclonal antibodies in infants on the burden of rsv infection in infancy;
describe the epidemiology of severe rsv disease in adults;
identify changes in recommendations for prevention of rsv infection.

Presentations:

10:30 AM – 10:55 AM US PT

RSV prevention in infants: Use and impact of maternal vaccines and infant monoclonal antibodies
Speaker: Helen Y. Chu, MD, MPH – University of Washington
10:55 AM – 11:20 AM US PT

RSV in adults: Epidemiology of severe RSV disease and RSV vaccines in the first year
Speaker: Fiona Havers, MD MHS (she/her/hers) – Centers for Disease Control and Prevention
11:20 AM – 11:45 AM US PT

This just in: Pediatric and adult RSV immunization policy updates for the 2024-25 respiratory virus season
Speaker: Amadea Britton, MD, SM – Centers for Disease Control and Prevention